---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-013437"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:42:27.607983+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aurinia Q1 net revenue $21.6M, net loss $37.6M; FY22 guidance reaffirmed

## Summary
- Net product revenue $21.6M (Q1 2021: $0.9M); net loss $37.6M ($0.27/shr) vs $50.4M ($0.40) YoY.
- Maintains FY2022 LUPKYNIS revenue guidance $115-$135M, representing 150-200% growth over FY2021.
- Patients on LUPKYNIS reached ~1,071 at March 31, 2022, up 21% from 884 at December 31, 2021.
- EMA review on track; European Commission decision expected in second half of 2022.
- Cash, cash equivalents and investments $418.8M at March 31, 2022, down from $466.1M at year-end 2021.

## SEC filing metadata
- accession: 0001628280-22-013437
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000162828022013437/0001628280-22-013437-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000162828022013437/auph-20220510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-013437
- JSON: https://secwatch.observer/filing/0001628280-22-013437.json
- Plain text: https://secwatch.observer/filing/0001628280-22-013437.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.